FDA approves GSK’s COVID antibody therapy

The United States Food and Drug Administration (FDA) gave an emergency use authorization (EUA) to GlaxoSmithKline’s coronavirus antibody therapy sotrovimab. The therapy is approved for patients with mild-to-moderate COVID-19 who are at high risk for progression to a severe illness.

The FDA stated the treatment is effective against the current circulating coronavirus variants. However, it added the safety and effectiveness of sotrovimab continue to be evaluated for the treatment of COVID-19.

Breaking the News / DJ